Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HBC 7 versus TRAVASOL 3 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HBC 7 versus TRAVASOL 3 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
AMINOSYN-HBC 7% vs TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-HBC 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, supporting anabolism and tissue repair in patients with high metabolic stress.
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES is a parenteral nutrition solution providing amino acids, electrolytes, and calories (as dextrose). Amino acids are used for protein synthesis, and electrolytes maintain acid-base balance and osmotic pressure.
Intravenous infusion; typical adult dose: 1.0-1.5 g/kg/day of amino acids, administered as a continuous infusion over 12-24 hours.
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour, adjusted to meet metabolic needs. Typical adult daily dose: 0.8-1.5 g amino acids/kg/day, equivalent to 23-43 mL/kg/day of TRAVASOL 3.5%.
None Documented
None Documented
Not applicable; amino acids are continuously metabolized and recycled. For individual amino acids, terminal half-life ranges from minutes to hours depending on metabolic demand.
Not applicable as a fixed half-life; amino acids have rapid plasma clearance (t1/2 of 10-30 minutes for individual amino acids). Clinical context: Continuous infusion maintains steady state.
Renal: >90% as amino acids and metabolites; minimal biliary/fecal elimination.
Renal: >95% of infused amino acids and electrolytes are excreted unchanged or as metabolites. Biliary/fecal: <5%.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution